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Abstract
Background: Surgery for trachomatous trichiasis (TT) is a key component of the SAFE Strategy for trachoma control.
Unfortunately, recurrent TT following surgery is common, probably due to various surgical and disease factors. To develop
strategies to reduce recurrence rates it is necessary to understand its pathological basis. In this study we investigated the
relationship between recurrent trichiasis and the expression of various cytokines and fibrogenic genes during a two-year
follow-up period.
Methodology/Principal Findings: Individuals undergoing surgery for TT were examined at baseline (pre-operative), 6, 12,
18 and 24 months. Conjunctival swab samples were collected from the tarsal conjunctiva for RNA isolation on each
occasion. Individuals who developed recurrent TT with at least 3 lashes touching the eye on one or more occasion were
designated ‘‘cases’’ and an equal number of ‘‘controls’’ were randomly selected from those without recurrent TT, frequency
matched for age and baseline TT severity. The expression of the following genes was measured by quantitative RT-PCR:
S100A7, IL1B, CXCL5, TNFA, NOS2A, CTGF, MMP7, MMP9 and MMP12. Thirteen hundred individuals were enrolled and
underwent surgery. By two years 122 had developed recurrent TT with at least 3 lashes touching the eye. Recurrent TT was
consistently associated across multiple time points with about a 2-fold increase in S100A7 expression (p = 0.008). Clinically
visible conjunctival inflammation was associated with increased S100A7, IL1B, CXCL5, MMP9 and MMP12 expression.
Conclusions/Significance: Increased S100A7 expression was associated with trachomatous conjunctival scarring and may
be linked to the pathophysiology of recurrent TT. S100A7 expression could be a potential biomarker for this disease process.
As part of the epithelial innate immune response S100A7 has multiple actions, potentially contributing to a chronic pro-
inflammatory response, which may lead to ongoing tissue damage and increased scarring.
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Introduction
Trachoma remains the leading infectious cause of blindness
worldwide [1]. Trachomatous Trichiasis (TT) is the potentially
blinding stage of this disease in which the eyelashes scratch the
surface of the globe, resulting in corneal opacification [2–4]. It is
the result of a progressive scarring process of the tarsal
conjunctiva, which is initiated in childhood by recurrent episodes
of Chlamydia trachomatis infection that are characterised by
inflammation. However, the pathophysiology of this scarring
process is poorly understood; it is unclear which immuno-
fibrogenic mechanisms are most important and what factors drive
disease progression, particularly in the late stages when C.tracho-
matis can rarely be detected [2,5].
Surgery is performed to correct TT. Unfortunately, TT
frequently recurs, particularly when performed under operational
conditions [2,6–8]. Recurrent TT is a significant problem in
preventing blindness from trachoma, undermining the potential
success of surgical programmes. Prospective long-term data
suggest that TT recurrence can be broadly subdivided into two
phases: early and late [2,9–12]. Early recurrence, which may be
defined as that developing within the first six months following
surgery, appears to occur with a greater incidence rate than late
recurrence [9].
Early recurrence is probably attributable to a combination of
factors including pre-operative disease severity, how well the
surgery was performed, and possibly early post-operative wound
healing responses [2,13]. Early trichiasis recurrence rates may be
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reduced by improving the quality of surgery and refining the
operative procedure [8,14]. Inter-surgeon variation in recurrence
rates has been reported, suggesting that operative factors can
significantly affect results [2,12,15]. Currently, the World Health
Organization (WHO) endorses the bilamellar and posterior
lamellar tarsal rotation procedures (BLTR and PLTR) [8,16].
The BLTR has been the subject of several clinical trials comparing
it to alternative procedures (other than the PLTR) and was found
to give the best results [10,17,18]. Currently, it is not know
whether the BLTR and PLTR are equally effective. There may
also be scope for improving results through influencing the course
of the post-operative wound healing process by regulating
excessive contractile scarring, analogous to glaucoma filtration
surgery. However, these early biological events have yet to be
studied.
Late recurrence is likely due to immune-mediated conjunctival
scarring disease, however, the pathological basis of progressive
cicatrisation in trachoma remains to be elucidated. It may be
driven by recurrent infection, yet, it is relatively unusual to detect
C. trachomatis infection in people with scarring trachoma, and it has
not been found to be a risk factor for recurrent TT [2,5,6,11,19].
In contrast, other non-chlamydial bacterial pathogens are
identified relatively frequently and have been associated with
recurrent trichiasis [2,19,20]. We have previously found such
infections to be associated with altered gene expression patterns for
inflammatory cytokines and tissue modifiers such as matrix
metalloproteinases (MMP) [20,21]. The potential of post-operative
oral azithromycin to reduce recurrence has been investigated. In
one trial from Ethiopia, a region with generally high C. trachomatis
prevalence, recurrence was reduced, although this was not linked
to C. trachomatis [11]. In a separate trial from The Gambia with a
lower prevalence of C. trachomatis, post-operative azithromycin did
not affect the recurrence rate [2]. Similarly, in a study from Nepal,
the recurrence rates were comparable in the azithromycin and
placebo groups [22].
A better understanding of the immuno-fibrogenic basis of
recurrent TT may help in developing interventions that reduce
recurrence that is attributable to the scarring disease process. We
have previously examined the conjunctival transcriptome in
scarring trachoma in a case-control study [5]. This identified
various factors that are differentially expressed in scarred
conjunctival tissue compared to normal controls: pro-inflamma-
tory cytokines and several MMPs were particularly prominent.
The gene with the largest relative increase in expression was the
pro-inflammatory, anti-bacterial peptide S100A7 or Psoriasin,
which was increased 15-fold in trichiasis cases before surgery,
compared to controls [5]. We have also previously reported the
conjunctival expression level of several factors at a single time
point one year after TT surgery and found recurrent TT was
associated with a reduced MMP1/TIMP1 ratio [20].
Recently we reported the results of a randomised controlled trial
of absorbable (vicryl) versus silk sutures for TT surgery; there was
no difference in outcome between the two treatment arms [12].
During this trial we re-examined participants at six-monthly
intervals for two years. On each occasion conjunctival swab
samples were collected for gene expression analysis. Here we
report the expression of various pro-inflammatory cytokines and
MMPs in a longitudinal comparison of trial participants with and
without recurrent TT. We examined the hypothesis that some of
these factors are linked to recurrent disease and sought to identify
biomarkers associated with recurrent TT.
Methods
Ethics statement
This study adhered to the tenets of the Declaration of Helsinki
and was approved by three science and ethics committees: the
National Health Research Ethics Review Committee, Ministry of
Science and Technology, Ethiopia, the London School of Hygiene
and Tropical Medicine Ethics Committee (UK) and Emory
University Institutional Review Board (Atlanta, USA). Potential
participants were provided with both written and oral information
in Amharic about the trial. For those agreeing to participate,
written informed consent in Amharic was required prior to
enrolment. If the participant was unable to read and write, the
information sheet and consent form were read to them and their
consent recorded by witnessed thumbprint, which was approved
by the Ethics Committees.
Participant selection and surgical treatment
This nested case-control study was conducted within a surgical
trial of absorbable versus silk sutures in the treatment of upper
eyelid TT in Amhara Region, Ethiopia, which has been reported
separately [12]. In brief, individuals aged 18 years or more with
previously un-operated major trachomatous trichiasis (.5 trichia-
tic lashes) of the upper eyelid were recruited through surgical
treatment campaigns in rural areas. Trichiasis was considered to
be due to trachoma in the absence of another obvious cause for the
trichiasis, such as trauma, malignancy, involutional changes or
severe blepharitis.
Following the baseline pre-operative clinical assessment (de-
scribed below), participants were randomised to one of two
surgical intervention groups, which differed only in the type of
sutures that were used. The posterior lamellar tarsal rotation
procedure was used in all cases to correct upper eyelid TT, using
the randomly allocated suture material: (1) PLTR with 4/0 silk
sutures (Mersilk, Ethicon) or (2) PLTR with 5/0 polyglactan-910
(Vicryl undyed, Ethicon) [8,12]. The PLTR was chosen because
this is the standard procedure used in Amhara Region. Five
general nurses performed all the surgery. They had been trained in
TT surgery by the Amhara Regional Trachoma control
programme, and had been performing surgery regularly for more
than 1 year. They were selected on the basis of their good
performance and underwent additional refresher and standard-
isation training, under the supervision of a senior Ethiopian
Author Summary
Trachoma causes blindness through corneal damage from
in-turned eyelashes (trachomatous trichiasis [TT]). Trichiasis
is treated surgically to correct the anatomical abnormality.
Unfortunately, TT frequently returns following surgery,
which again puts the person at risk of sight loss. Recurrent
trichiasis is multifactorial. We investigated the possible role
of various immuno-fibrogenic factors. To do this we
operated on 1300 people with TT and followed them up
every six months for a two-year period. On each occasion a
conjunctival swab was collected for human gene expres-
sion analysis. We measured various factors that are
thought to be important in inflammation and scarring
diseases. The gene expression profile of people who
developed recurrent TT was compared to a sample of
those that did not have a recurrence. Recurrent TT was
associated with increased expression of psoriasin (S100A7)
before surgery and on multiple occasions during a two-
year follow-up period. S100A7 is able to promote
inflammation and may contribute to the development of
the scarring process in trachoma.
Psoriasin (S100A7) and Recurrent Trichiasis
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ophthalmologist [12]. Postoperatively, the operated eye was
padded for a day and then tetracycline eye ointment was self-
administered twice a day for two weeks.
Participants were re-examined at 6, 12, 18 and 24 months after
surgery. To be eligible for analysis in this study a complete follow-
up series was required; cases and controls were only selected from
those individuals who were examined on all occasions. Individuals
who developed any recurrent TT (defined as one or more lashes
touching the eye) at any point during the course of the two-year
follow-up period were designated recurrent TT ‘‘cases’’ and those
without any trichiasis recurrence or evidence of epilation at any
time point were designated non-recurrent ‘‘controls’’. We further
limited recurrent TT cases to those that had 3 or more lashes
touching the eye at some point during follow-up, as this provided
just over 100 recurrent TT cases for analysis. The non-recurrent
controls were selected at random from operated individuals who
had not developed recurrent TT at any time point during follow-
up; these controls were frequency matched with the recurrent
cases for age and baseline trichiasis disease severity (determined by
the number of lashes touching the eye before surgery).
Clinical assessment and sample collection
At all assessments participants were examined for clinical signs
of trachoma, graded using 2.56binocular loupes according to the
detailed WHO trachoma grading system [23]. The baseline (pre-
surgery), 12-month and 24-month follow-up examinations were
conducted by a single ophthalmologist (SR); the 3, 6 and 18-
month examinations were conducted by a single ophthalmic nurse
(EH). Recurrent trichiasis was defined as one or more lashes
touching the eye. In preparatory exercises the examiners were
standardised to each other and showed strong agreement for the
presence of trichiasis (kappa= 0.86). The number of lashes
touching the eye in primary position was counted. Individuals
with clinical evidence of epilation were considered to have
recurrent trichiasis, even if no lashes were touching the globe on
examination. Significant conjunctival inflammation was defined as
the presence of papillary inflammation grades P2 or P3 of the
detailed WHO Trachoma Grading System [23].
Conjunctival swab samples were collected by the examiner from
the upper tarsal conjunctival surface for RNA isolation at all time-
points, except 3-months. The ocular surface was anaesthetised
with preservative-free proxymetacaine 0.5% eye drops (Minims,
Chauvin Pharmaceuticals). A dacron polyester-tipped swab
(Hardwood Products Company) was passed horizontally across
the conjunctival surface 4 times with a quarter turn between each
pass. Swabs were then placed directly into a tube containing
0.3 ml of RNAlater (Life Technologies). Samples were kept on ice
packs until frozen later the same day at 220uC.
Quantitative RT-PCR
The abundance of nine selected transcripts was estimated by
quantitative RT-PCR. The choice of targets was informed by our
previously published conjunctival transcriptome analysis conduct-
ed on pre-operative samples from TT patients in the same
population and matched normal controls [5]. These targets
broadly fall into three groups: (i) pro-inflammatory cytokines,
chemokines or effector molecules (interleukin-1b [IL1B], tumour
necrosis factor-a [TNFA], psoriasin-1 [S100A7], chemokine (CXC)
ligand-5 [CXCL5], nitric oxide synthase-2A [NOS2A]), (ii) various
matrix metalloproteinases (MMP7, MMP9 and MMP12) and (iii)
connective tissue growth factor (CTGF).
Total RNA was extracted from the swab samples using the
RNeasy Micro Kit (Qiagen). Reverse transcription was performed
using the QuantiTect Reverse Transcription Kit (Qiagen)
according to the manufacturer’s instructions. Multiplex real-time
quantitative PCR was performed on a Rotor-Gene 6000 (Corbett
Research, Cambridge, UK) using the QuantiTect Multiplex
NoROX Kit (Qiagen), according to the manufacturer’s instruc-
tions. Multiplex assays of up to four separate targets (including
HPRT-1 as the reference gene) were designed by Sigma Life
Science (www.Sigma.com/designmyprobe) using Beacon Designer
7.60 (Premier Biosoft International, Palo Alto, CA, USA). The
thermal cycle protocol used the following conditions: 95uC for
15 minutes, followed by 45 cycles of (1) denaturation at 94uC for
30 seconds, (2) annealing and extension at 60uC for 30 seconds.
Fluorescence data was acquired at the end of each cycle. The
relative efficiency of the component reactions was assessed using
standards containing all targets in a sequence of tenfold serial
dilutions. Reactions were performed in duplicate, in a total volume
of 25 ml, which contained 2 ml of sample or standard. Probe and
primer sequences are available on request.
Analysis
We aimed to analyse sample sets from at least 100 cases and 100
controls. This sample size was estimated to have 80% power and
95% confidence to detect a factor with an odds ratio of 2.5 that is
present in 50% of the controls. The maximum number of lashes
touching the eye during follow-up was used to stratify the
recurrent TT group.
The transcript abundances for genes of interest were standard-
ised relative to that of HPRT-1 in the same reaction using the
DDCT method and were successfully normalised by log10
transformation [24]. This corrects for variations in the total
RNA collected by the swabs. The only exception was CTGF,
which was not possible to multiplex with these other targets;
therefore the quantitation for this target relative to HPRT is based
upon standard curve analysis.
Data were managed in Access (Microsoft) and analysed in
STATA 11 (StataCorp). Cases and controls were comparable in
terms of age, sex and pre-operative trichiasis severity, therefore,
the relative level of expression of each target was compared
between them using unadjusted unpaired t tests. Multivariable
linear regression models were fitted for the expression level of each
target at baseline and the following potential explanatory
variables: sex (female), age (in years), case-control status, conjunc-
tiva inflamed (P2/P3) at baseline and the number of lashes
touching the eye at baseline. A stepwise selection process was
performed to fit each model, retaining terms if the p-value for
omission was ,0.2 and their p-value in the model was ,0.2, with
p-values assessed by the likelihood ratio test. Similar models were
fitted for each follow-up time point. There was no evidence of a
differential effect over time, assessed by likelihood ratio testing
with and without an interaction with time (p-values 0.19 to 0.74).
Therefore, we combined the data from the four follow-up time
points, using random-effects linear models. An un-conditional
logistic regression model was developed for the association
between recurrent trichiasis and baseline conjunctival inflamma-
tion and the expression levels of all nine genes. Again a stepwise
selection process was performed to fit each model, retaining terms
if the p-value for omission was ,0.2 and their p-value in the model
was ,0.2, with p-values assessed by the likelihood ratio test. The
correlation in the expression of the various targets at each time
point was investigated using biplots and partial correlation
coefficients. To adjust for multiple comparisons, we calculated
critical significance thresholds for each table using the conservative
Bonferroni correction. Although we make several comparisons,
these are un-likely to be truly independent of each other, as one
Psoriasin (S100A7) and Recurrent Trichiasis
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would expect some of these genes to interact in biological
networks.
Results
Participant selection and characteristics
A total of 1300 individuals with major TT were recruited into
the trial and received trichiasis surgery [12]. As there was no
difference in the TT recurrence rate between the two alternative
sutures, subjects for this nested case-control study were drawn
from both trial arms and data combined [12]. In all, 901/1300
(69.3%) were assessed at all five time-points. Only those seen and
sampled on all five occasions were eligible for this nested study.
Comparing the eligible and excluded people: there was no
difference in the proportion who were female (p = 0.3), the eligible
group was slightly younger (49 years vs. 51 years, t-test p= 0.02)
and had slightly more severe baseline trichiasis (mean number of
lashes: 8.0 vs. 7.3, Wilcoxon rank-rum p= 0.006 There were 122
people (seen and sampled five times) who developed recurrent
trichiasis of the upper eyelid with three or more lashes touching
the eye during the follow-up period; these participants were
designated as recurrent ‘‘cases’’.
There were 740 people (seen and sampled five times) who had
no evidence of recurrent TT at any point during the follow-up
period. Overall, the non-recurrent group tended to be younger
(mean age 48.3 years, compared to 54.1 years, t-test p,0.0001)
and had less severe pre-operative trichiasis (mean number of lashes
7.1, compared to 13.8 lashes, Wilcoxon rank-rum p,0.0001)
compared to the recurrent TT cases. To ensure that the non-
recurrent ‘‘control’’ group was of a similar age and preoperative
trichiasis severity, 122 individuals were randomly selected from the
potential 740, constrained by frequency matching from within the
same combination of age group (18–29, 30–39, 40–49, 50–59, 60–
69, 70+ years) and pre-operative trichiasis severity group (0
(epilating), 1–5, 6–9, 10–19, 20+ lashes) as the 122 recurrent TT
cases. The baseline distribution of age and trichiasis severity
groups were the same for cases and controls, except in one
instance, where there was one too few controls to frequency match
(Table 1). There was no difference in gender, age, baseline
trichiasis severity or suture randomisation arm between cases and
controls (Table 2). All cases and controls had tarsal conjunctival
scarring at baseline. However, individuals who subsequently
developed recurrent trichiasis were more likely to have had tarsal
conjunctival inflammation (P2/P3) than the controls pre-opera-
tively.
Samples
A total of 1220 samples had been collected across the five time
points from these 244 participants. The nine targets were
measured in each of these. There were a small number of samples
from each time point for which it was not possible to perform
quantitative PCR due to an inadequate RNA sample (Baseline
four samples; 6-months three samples; 12-months eleven samples;
18-months six samples; 24-months four samples). For the purpose
of this analysis these samples are treated as missing data.
Gene expression analysis
There was no significant difference between the two trial arms
in the expression of any of the targets at any of the time-points.
Therefore, the data are not adjusted for trial arm. Recurrent TT
was consistently associated with about a 2-fold increase in S100A7
(at the 0.05 level), on 4 out of 5 occasions. No other targets had a
consistent association with recurrent TT (Table 3). Clinically
apparent conjunctival inflammation (P2/P3), irrespective of
whether there was recurrent TT or not, was consistently associated
with increased expression of pro-inflammatory factors (S100A7,
IL1B, CXCL5) and matrix metalloproteinases (MMP9, MMP12)
across multiple time points (Table 4). Multivariable linear
regression models for each target were fitted for baseline and a
combination of the follow-ups (random-effects model), Table 5.
Recurrent trichiasis remained significantly associated with in-
creased expression of S100A7 after adjusting for other factors in
these models, both before and after surgery. In an un-conditional
logistic regression model for recurrent trichiasis and baseline
factors, only conjunctival inflammation and S100A7 expression
were significantly associated with subsequent recurrence (Table 6).
Partial correlation coefficients were calculated for each target
with each other for each time point. The total number of
Table 1. Baseline distribution of age groups and trichiasis severity groups for both cases (Ca) and controls (Co).
Age Group (Years) Total number of lashes
0 (epilating) 1–5 6–9 10–19 20+ Total
Ca Co Ca Co Ca Co Ca Co Ca Co Ca Co
18–29 0 0 0 0 0 0 2 2 2 2 4 4
30–39 0 0 5 5 5 5 3 3 2 2 15 15
40–49 3 3 9 9 5 5 10 10 4 4 31 31
50–59 2 2 6 6 15 15 3 3 10 11 36 37
60–69 2 2 11 11 4 4 6 6 6 5 29 28
70+ 0 0 1 1 1 1 3 3 2 2 7 7
Total 7 7 32 32 30 30 27 27 26 26 122 122
doi:10.1371/journal.pntd.0001985.t001
Table 2. Baseline demographic and clinical characteristics.
Cases Controls P-value
Gender (female) 91/122 (74.6%) 94/122 (77.1%) 0.65
Age (mean) 54.1 (SD 12.6) 53.6 (SD 11.8) 0.75
Lash count (mean) 13.8 (SD 17.0) 14.6 (SD 17.2) 0.79
Suture type (silk) 61/122 (50.0%) 55/122 (45.0%) 0.44
Clinically inflamed (P2/P3) 94/122 (77.1%) 76/122 (62.3%) 0.012
doi:10.1371/journal.pntd.0001985.t002
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significant partial correlations at the 0.05 level is represented in
Figure 1. Consistent associations were found on 4 or 5 occasions
between (1) S100A7 and NOS2A, (2) IL1B and CXCL5, (3) IL1B and
TNFA, (4) NOS2A and MMP7, and (5) MMP9 and MMP12.
Discussion
Recurrent trichiasis is a challenging problem for prevention of
blindness programmes as it renders the surgical intervention less
effective, increasing the risk of sight loss. Multiple factors likely
contribute to recurrence, which can broadly be subdivided into
disease related and surgery related factors. Refinements of the
operative procedure and improvements in surgical quality are
anticipated to lead to a reduction in early recurrent trichiasis
[2,14]. However, the risk of recurrence is also related to the
severity of pre-operative disease and probably individual variations
in early wound-healing events and therefore attributable to the
underlying cicatricial disease process [2,12,25]. In this study we
aimed to identify immuno-fibrogenic factors associated with
recurrent TT developing over a two-year period.
The choice of targets for this longitudinal gene expression study
was guided by findings from the baseline case-control study of the
conjunctival transcriptome, which compared individuals with
established TT to people without disease from the same
population [5]. This earlier study used a two-stage process to
identify potential disease biomarkers and pathways: (1) transcrip-
tome-wide microarray analysis, followed by (2) quantitative PCR
in a large sample set to confirm findings. This identified a variety
of pro-inflammatory (IL1B, TNFA, S100A7, CXCL5, NOS2A) and
tissue remodelling factors (MMP7, MMP9 and MMP12), which
were associated with conjunctival scarring and trichiasis before
surgery. Therefore, these were chosen as candidates to be
investigated in this longitudinal study of recurrent trichiasis
following surgery.
In the present study the only gene found to have consistently
increased conjunctival expression (both before and after surgery) in
individuals who developed recurrent trichiasis was S100A7
(Psoriasin). There was an approximately 2-fold increase in its
expression on four out of the five time-points; this association
remained significant after adjustment was made for other potential
explanatory factors. Clinically visible conjunctival inflammation
(P2/P3) was also associated with increased expression of S100A7.
Multivariable models indicated that the associations between
recurrent trichiasis, S100A7 expression and inflammation were
independent. Unsurprisingly, the expression of several pairs of
factors showed a degree of association on multiple occasions.
Table 3. Gene expression level in recurrent TT cases relative to non-recurrent controls.
Target Baseline 6-months 12-months 18-months 24-months
FC P-value FC P-value FC P-value FC P-value FC P-value
S100A7 1.95 0.015 2.05 0.006 1.64 0.08 2.55 0.0012 1.96 0.022
IL1B 1.19 0.36 1.02 0.92 1.54 0.014 1.34 0.049 1.07 0.71
CXCL5 1.33 0.30 1.04 0.85 1.06 0.76 1.45 0.08 1.04 0.86
TNFA 1.05 0.72 1.10 0.42 1.05 0.68 1.17 0.12 1.07 0.62
NOS2A 1.21 0.11 1.07 0.59 1.06 0.62 1.18 0.14 1.18 0.30
CTGF 1.27 0.22 1.27 0.039 1.12 0.34 1.16 0.22 1.11 0.45
MMP7 1.13 0.32 1.18 0.16 1.03 0.80 1.33 0.022 1.16 0.25
MMP9 1.17 0.25 1.03 0.82 1.24 0.10 1.38 0.0087 1.23 0.12
MMP12 1.02 0.90 1.02 0.90 1.14 0.34 1.42 0.012 1.05 0.74
FC fold change; P values for unpaired t test. Using the Bonferroni correction, the critical significance threshold level is a P value of ,0.0011.
doi:10.1371/journal.pntd.0001985.t003
Table 4. Gene expression level in inflamed (P2/P3) individuals relative to non-inflamed individuals.
Target Baseline 6-months 12-months 18-months 24-months
FC P-value FC P-value FC P-value FC P-value FC P-value
S100A7 1.87 0.037 2.67 0.013 3.78 ,0.0001 2.49 0.0016 4.13 ,0.0001
IL1B 1.44 0.08 1.85 0.013 2.08 ,0.0001 2.03 ,0.0001 1.95 0.0009
CXCL5 2.27 0.0075 1.75 0.10 2.38 ,0.0001 2.16 0.0002 1.66 0.038
TNFA 1.03 0.83 1.17 0.37 1.35 0.0088 1.19 0.079 1.09 0.57
NOS2A 1.07 0.62 1.44 0.043 1.36 0.013 1.25 0.051 1.29 0.14
CTGF 1.31 0.19 1.13 0.49 1.05 0.70 1.10 0.43 1.23 0.16
MMP7 1.06 0.67 1.13 0.50 1.11 0.44 1.13 0.32 1.45 0.010
MMP9 1.32 0.059 1.35 0.10 1.59 0.0005 1.41 0.0051 1.57 0.0017
MMP12 1.46 0.028 1.66 0.0077 1.52 0.0023 1.80 ,0.0001 1.51 0.018
FC fold change; P values for unpaired t test. Using the Bonferroni correction, the critical significance threshold level is a P value of ,0.0011.
doi:10.1371/journal.pntd.0001985.t004
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We previously found S100A7 to be the most strongly up-
regulated gene in the conjunctiva in TT cases relative to normal
controls, in the same Ethiopian population and in Tanzanians
with conjunctival scarring in the absence of TT [5,26]. The
increase was more marked when the conjunctiva appeared
inflamed (P2/P3) [5,26]. We have also found S100A7 expression
to be significantly increased in children with signs of clinically
active trachoma [21]. However, it is difficult to determine in this
longitudinal study following trichiasis surgery the potential
contribution that S100A7 might make to the pathophysiology of
recurrent trichiasis or progressive conjunctival scarring in general.
At present there are no suitable animal models for this scarring
process that can be manipulated to investigate its potential role.
Psoriasin is a member of the S100 family, a diverse group of
calcium binding, low molecular weight proteins, which are
expressed in multiple tissues, particularly epithelial surfaces [27].
S100A7 was initially identified in psoriatic skin lesions, and linked
to the inflammatory pathophysiology of the disease [28]. In
healthy skin it is expressed only at minimal levels. Subsequently, it
was found to be increased in other inflammatory skin conditions
[27]. A number of epithelium-associated malignancies have
increased expression of S100A7: carcinoma of the breast, lung,
prostate, stomach and cutaneous squamous cell carcinoma.
Aggressive tumour behaviour (invasion and metastasis) has been
particularly associated with its expression [29–33]. S100A7
appears to mediates these effects through increasing inflammation
and activation of MMPs, which have parallels in trachoma
[34,35]. More recently, S100A7 has been identified as a potential
biomarker for Alzheimer’s disease, with marked increases in both
cerebrospinal fluid and brain tissue [36].
Table 5. Multivariable linear regression models for the
expression of each target at baseline and follow-up.
Target Baseline Follow-up
FC P-value FC P-value
S100A7
Gender (female) 2.12 0.013 1.89 0.015
Age (years) - - 1.03 0.002
Inflammation (P2/P3) - - 1.99 ,0.001
Recurrent TT case 2.07 0.005 1.78 0.008
Baseline lashes* 1.04 ,0.001 - -
IL1B
Gender (female) 1.49 0.069 - -
Age (years) 1.01 0.057 1.01 0.001
Inflammation (P2/P3) 1.29 0.194 1.54 ,0.001
Recurrent TT case - - - -
Baseline lashes* 1.03 ,0.001 - -
CXCL5
Gender (female) 1.52 0.205 1.34 0.105
Age (years) 1.02 0.039 1.03 ,0.001
Inflammation (P2/P3) 2.05 0.017 1.44 ,0.001
Recurrent TT case - - - -
Baseline lashes* 1.02 0.005 - -
TNFA
Gender (female) 1.84 ,0.001 1.24 0.014
Age (years) 1.01 0.021 1.01 0.001
Inflammation (P2/P3) - - - -
Recurrent TT case - - - -
Baseline lashes* 1.01 0.005 - -
NOS2A
Gender (female) 1.57 0.001 1.40 0.001
Age (years) - - 1.02 ,0.001
Inflammation (P2/P3) - - 1.14 0.036
Recurrent TT case 1.24 0.063 - -
Baseline lashes* 1.01 0.003 - -
CTGF
Gender (female) - - - -
Age (years) 1.01 0.080 0.99 0.008
Inflammation (P2/P3) - - 1.18 0.004
Recurrent TT case 1.30 0.156 1.13 0.122
Baseline lashes* 1.02 ,0.001
MMP7
Gender (female) - - - -
Age (years) - - 1.01 0.108
Inflammation (P2/P3) - - 1.17 ,0.001
Recurrent TT case - - - -
Baseline lashes* - - - -
MMP9
Gender (female) 1.44 0.013 1.25 0.027
Age (years) - - 1.01 ,0.001
Inflammation (P2/P3) - - 1.44 ,0.001
Recurrent TT case 1.21 0.129 1.14 0.114
Table 5. Cont.
Target Baseline Follow-up
FC P-value FC P-value
Baseline lashes* 1.02 ,0.001
MMP12
Gender (female) 1.58 0.011 1.25 0.031
Age (years) - - 1.01 0.001
Inflammation (P2/P3) 1.36 0.066 1.29 ,0.001
Recurrent TT case - - - -
Baseline lashes* 1.02 ,0.001 - -
*Baseline lashes were only included as a potential term in the baseline models.
The four follow-up assessments were combined using random-effects models.
Terms were only retained in the models if their p-value was ,0.2, by likelihood
ratio testing.
doi:10.1371/journal.pntd.0001985.t005
Table 6. Unconditional logistic regression model for baseline
factors that associated with recurrent trichiasis.
Variable OR 95% C.I. p-value
Inflammation (P2/
P3)
1.81 1.02–3.21 0.041
S100A7 expression 1.36 1.03–1.81 0.033
Only baseline inflammation and S100A7 expression level met the criteria to be
retained.
doi:10.1371/journal.pntd.0001985.t006
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The functions of S100A7 have only recently begun to be
explored in detail. It is an anti-microbial peptide, protecting
epithelial surfaces from bacterial infection [37–40]. The mecha-
nism by which S100A7 exerts its direct antimicrobial effect is not
fully understood; it is possibly through pore-formation, which
permeabilises the bacterial cell membrane, or through zinc
sequestration [37,38]. S100A7 also has some chemokine-like
actions and may be particularly important in driving an innate
immune response. It is chemotactic to both neutrophils and T
lymphocytes [41–43]. It has been shown to stimulate neutrophils
to produce various pro-inflammatory factors (TNFa, IL-6, IL-8,
CCL3, CCL4, CCL20), produce reactive oxygen species (ROS)
through NADPH oxidase, and to degranulate, releasing myelo-
peroxidase [44]. S100A7 has also been shown to cause keratino-
cytes to produce cytokines that probably promote Th1 and Th17
responses (TNFa, IL-1a, IL-23, MIP2, RAGE) [43]. Interestingly,
stimulation of keratinocytes with a combination of IL-17A, IL-22
and TNFa increased S100A7 production, which may form a feed-
back loop, amplifying inflammation in psoriasis and other
conditions [43].
Little is known about the regulation of S100A7. Some bacterial
components, such as flagellin, trigger increased production of
S100A7, probably through TLR5 [45]. In addition, S100A7
production can also be stimulated by pro-inflammatory cytokines
(TNFa, IL-1a, IL-6, IL-17, IL-22) [33,43,46]. In breast cancer cell
lines, IFNc down-regulates S100A7 expression, through STAT1
transcriptional activity [47]. This may be of relevance to
trachoma, as Th1 responses (characterized by increased IFNc)
are thought to be associated with a less scarred outcome, which
could conceivably be partly mediated through suppression of
S100A7 [48].
Chronic conjunctival inflammation is an important component
of the pathophysiology of trachoma and it is a relatively frequent
finding in people with cicatricial disease [2,49]. Repeated or
persistent inflammation in childhood and early adult life is
associated with scarring complications later in life [50,51]. The
expression of IL1B, CXCL5, MMP9 and MMP12 were increased in
the presence of clinical inflammation on several occasions. We
have previously reported associations between IL1B and MMP9
and conjunctival inflammation following surgery [20]. These
factors are plausibly involved in inducing and regulating inflam-
mation in the conjunctiva and may contribute to the underlying
disease process, although in this study they were not associated
with recurrent trichiasis. The expression of TNFA was not
consistently associated with inflammation (only one occasion),
which is a pattern we have found in two earlier studies [5,20].
This study has a number of potential limitations. The outcome
of interest was recurrent trichiasis. This can be a variable sign
especially if the patient is practicing epilation. However, careful
note was made of any evidence of epilation on examination.
Secondly, measuring the expression of a gene does not necessarily
equate to functional activity of its protein product. Positive
findings will need further validation with alternative approaches,
such as immunohistochemistry to detect the protein. We did not
perform PCR testing for C. trachomatis because in this population
(which has an active azithromycin mass distribution programme)
at baseline we have previously reported that infection was very
rare in adults with and without TT (0.1%) and therefore
considered it unlikely to be informative [5].
Anti-scarring therapies are increasingly used in ophthalmic
surgery to limit cicatricial complication [52]. For example, specific
inhibitors of TGFb and MMPs are being investigated for use in
glaucoma filtration surgery. We did not identify obvious potential
therapeutic targets, such as a MMPs associated with recurrent
trichiasis. It is possible that the MMPs play a role in the outcome
of early post-operative wound healing events, although this was
not the focus on this study. The observation that increased
expression of S100A7 was consistently associated with recurrent
trichiasis indicates that it may have a role in this disease process. In
the light of new information becoming available about the
contribution of S100A7 to other diseases, our findings suggest
that this molecule warrants further investigation in trachoma.
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